(Q33702355)

English

Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease (English)

1 reference

Europe PubMed Central

28 July 2017

autosomal dominant polycystic kidney disease

0 references

autosomal dominant polycystic kidney

1 reference

based on heuristic

inferred from title

Ron T Gansevoort

16

object named as

Ron T Gansevoort

1 reference

Europe PubMed Central

28 July 2017

1

object named as

Esther Meijer

1 reference

Europe PubMed Central

28 July 2017

Niek F Casteleijn

4

object named as

Niek F Casteleijn

1 reference

Europe PubMed Central

28 July 2017

author name string

Joost P H Drenth

2

1 reference

Europe PubMed Central

28 July 2017

Hedwig d'Agnolo

3

1 reference

Europe PubMed Central

28 July 2017

Johan W de Fijter

5

1 reference

Europe PubMed Central

28 July 2017

Tom J Gevers

6

1 reference

Europe PubMed Central

28 July 2017

Peter Kappert

7

1 reference

Europe PubMed Central

28 July 2017

Dorien J M Peters

8

1 reference

Europe PubMed Central

28 July 2017

Mahdi Salih

9

1 reference

Europe PubMed Central

28 July 2017

Darius Soonawala

10

1 reference

Europe PubMed Central

28 July 2017

Edwin M Spithoven

11

1 reference

Europe PubMed Central

28 July 2017

Vicente E Torres

12

1 reference

Europe PubMed Central

28 July 2017

Folkert W Visser

13

1 reference

Europe PubMed Central

28 July 2017

Jack F M Wetzels

14

1 reference

Europe PubMed Central

28 July 2017

Robert Zietse

15

1 reference

Europe PubMed Central

28 July 2017

DIPAK Consortium

17

1 reference

Europe PubMed Central

28 July 2017

publication date

15 December 2013

1 reference

Europe PubMed Central

28 July 2017

American Journal of Kidney Diseases

1 reference

Europe PubMed Central

28 July 2017

63

1 reference

Europe PubMed Central

28 July 2017

3

1 reference

Europe PubMed Central

28 July 2017

446-455

1 reference

Europe PubMed Central

28 July 2017

Diagnosis and management of polycystic liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Somatostatin analog therapy for severe polycystic liver disease: results after 2 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Somatostatin analogues for treatment of polycystic liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Treatment strategies and clinical trial design in ADPKD

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Autosomal dominant polycystic kidney disease: the last 3 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Stability of selected serum proteins after long-term storage in the Janus Serum Bank

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Unified criteria for ultrasonographic diagnosis of ADPKD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Clinical practice. Autosomal dominant polycystic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Variation in age at ESRD in autosomal dominant polycystic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Evaluation of a gastrointestinal symptoms questionnaire

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Understanding pathogenic mechanisms in polycystic kidney disease provides clues for therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Optimal care of autosomal dominant polycystic kidney disease patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Chromosome 4 localization of a second gene for autosomal dominant polycystic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

21 June 2018

Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

30 October 2018

Stability of creatinine and cystatin C in whole blood

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

30 October 2018

Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

30 October 2018

The long-term outcome of patients with polycystic liver disease treated with lanreotide.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

30 October 2018

Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

30 October 2018

Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

30 October 2018

Everolimus in patients with autosomal dominant polycystic kidney disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

30 October 2018

Sirolimus and kidney growth in autosomal dominant polycystic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

30 October 2018

Randomized intervention studies in human polycystic kidney and liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

30 October 2018

Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

30 October 2018

Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

30 October 2018

Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

30 October 2018

Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

30 October 2018

Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

30 October 2018

Renal hemodynamic effects of somatostatin are not related to inhibition of endogenous insulin release

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042404

30 October 2018

Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24342522

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort

1 reference

https://pubmed.ncbi.nlm.nih.gov/24342522

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24342522

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Extrarenal manifestations of autosomal dominant polycystic kidney disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24342522

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/24342522

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Polycystic kidney disease: The complete structure of the PKD1 gene and its protein

1 reference

https://pubmed.ncbi.nlm.nih.gov/24342522

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency

1 reference

https://pubmed.ncbi.nlm.nih.gov/24342522

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/24342522

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1053/J.AJKD.2013.10.011

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33702355&oldid=2006856148"